The first CAR-Treg clinical trial has been granted authorization in the UK and the Netherlands (STEADFAST) applying anti-HLA-A2 CD4 Tregs in kidney transplant patients (EUCTR2019-001730-34-NL). This evidence concerns the gene CD4 and urogenital neoplasm.